It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?
作者信息
Ghanei Mostafa
机构信息
Chemical Injuries Research Centre, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
出版信息
Arch Med Sci. 2021 Feb 26;17(2):546-550. doi: 10.5114/aoms/130647. eCollection 2021.
Abstract
摘要
相似文献
1
It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?是时候在合适的时间窗内基于新冠病毒感染的病理生理学考虑一种抗炎疗法了吗？
Arch Med Sci. 2021 Feb 26;17(2):546-550. doi: 10.5114/aoms/130647. eCollection 2021.
2
Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR.小豆蔻提取物的抗炎反应和通过使用 RT-PCR 评估炎症标志物预测 COVID-19 患者的治疗窗。
Inflammopharmacology. 2022 Jun;30(3):883-894. doi: 10.1007/s10787-022-00951-x. Epub 2022 Mar 23.
3
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.EULAR 关于 COVID-19 发病机制和免疫调节治疗应用的考虑要点。
Ann Rheum Dis. 2021 Jun;80(6):698-706. doi: 10.1136/annrheumdis-2020-219724. Epub 2021 Feb 5.
4
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?吡非尼酮在抗击由 SARS-CoV-2 引起的炎症和纤维化状态中的附加价值：抗炎和抗纤维化治疗能否解决感染的肺部并发症？
Eur J Clin Pharmacol. 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4. Epub 2020 Jun 27.
5
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.皮下注射沙利鲁单抗治疗中重度 COVID-19 感染住院患者与标准治疗（SARCOVID）的比较：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 9;21(1):772. doi: 10.1186/s13063-020-04588-5.
6
COVID-19 exacerbating ESRD induced pericardial effusion requiring pericardial window: A case report.新冠病毒肺炎加重终末期肾病所致心包积液并需行心包开窗引流术：一例报告
Int J Surg Case Rep. 2023 Aug;109:108565. doi: 10.1016/j.ijscr.2023.108565. Epub 2023 Jul 26.
7
[Anti-inflammatory therapies for SARS-COV2 infection from a hematological perspective].[从血液学角度看针对SARS-CoV-2感染的抗炎疗法]
Rev Med Chil. 2020 Nov;148(11):1640-1646. doi: 10.4067/S0034-98872020001101640.
8
Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19.血清淀粉样蛋白A——新型冠状病毒肺炎相关高炎症综合征的潜在治疗靶点
Front Med (Lausanne). 2023 Mar 16;10:1135695. doi: 10.3389/fmed.2023.1135695. eCollection 2023.
9
[SARS-CoV-2 infection as a thrombo-inflammatory endothelial disease].[新型冠状病毒肺炎作为一种血栓性炎症性内皮疾病]
Rev Med Chil. 2020 Oct;148(10):1467-1474. doi: 10.4067/S0034-98872020001001467.
10
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.秋水仙碱在新型冠状病毒感染晚期的主动抗炎治疗。COLORIT 研究的初步结果。
Kardiologiia. 2021 Mar 1;61(2):15-27. doi: 10.18087/cardio.2021.2.n1560.
引用本文的文献
1
Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.接受药物免疫抑制治疗患者的新冠病毒感染结局。一项瑞士队列研究。
Arch Med Sci. 2022 Aug 3;21(3):845-851. doi: 10.5114/aoms/152340. eCollection 2025.
2
Antiviral Intervention of COVID-19: Linkage of Disease Severity with Genetic Markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760).2019冠状病毒病的抗病毒干预：疾病严重程度与基因标记FGB（rs1800790）、NOS3（rs2070744）和TMPRSS2（rs12329760）的关联
Viruses. 2025 May 30;17(6):792. doi: 10.3390/v17060792.
3
Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment.纳米颗粒：新冠病毒预防、诊断与治疗的一项突破。
Arch Med Sci. 2021 Oct 15;19(5):1410-1420. doi: 10.5114/aoms/142103. eCollection 2023.
4
Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.托珠单抗、血浆置换及其联合治疗重症 COVID-19 的疗效和安全性：一项随机临床试验。
Int Immunopharmacol. 2023 Feb;115:109623. doi: 10.1016/j.intimp.2022.109623. Epub 2022 Dec 21.
5
3D engineered tissue models for studying human-specific infectious viral diseases.用于研究人类特异性感染性病毒疾病的3D工程组织模型。
Bioact Mater. 2022 Sep 22;21:576-594. doi: 10.1016/j.bioactmat.2022.09.010. eCollection 2023 Mar.
本文引用的文献
1
Tocilizumab in severe COVID-19.托珠单抗治疗重症新型冠状病毒肺炎
Arch Med Sci. 2020 Jul 16;16(6):1457-1458. doi: 10.5114/aoms.2020.97411. eCollection 2020.
2
Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review.羟氯喹对新冠病毒病有效，且早期使用时疗效持续：一项系统评价
New Microbes New Infect. 2020 Nov;38:100776. doi: 10.1016/j.nmni.2020.100776. Epub 2020 Oct 5.
3
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.抗病毒药物的组织分布会影响其在 COVID-19 治疗中降低病毒载量的能力。
Eur J Pharmacol. 2020 Dec 15;889:173634. doi: 10.1016/j.ejphar.2020.173634. Epub 2020 Oct 6.
4
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
5
Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence.COVID-19 患者的抗血栓治疗？-理由和证据。
Int J Cardiol. 2021 Feb 1;324:261-266. doi: 10.1016/j.ijcard.2020.09.064. Epub 2020 Sep 28.
6
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study.生物制剂或小分子药物治疗的伦巴第和马尔凯风湿患者人群中 COVID 感染的流行情况：一项多中心回顾性研究。
J Autoimmun. 2021 Jan;116:102545. doi: 10.1016/j.jaut.2020.102545. Epub 2020 Sep 22.
7
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials".羟氯喹在 COVID-19 中无益：随机对照试验的系统评价和荟萃分析结果。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1673-1680. doi: 10.1016/j.dsx.2020.08.033. Epub 2020 Sep 1.
8
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.COVID-19 与风湿性自身免疫性系统性疾病：一项大型意大利患者系列报告。
Clin Rheumatol. 2020 Nov;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7. Epub 2020 Aug 27.
9
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.中国湖北省风湿性疾病患者的新冠肺炎：一项多中心回顾性观察研究
Lancet Rheumatol. 2020 Sep;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7. Epub 2020 Jul 3.
10
Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.《COVID-19 细胞因子风暴：免疫病理机制、临床考量与治疗策略：REPROGRAM 联盟立场文件》。
Front Immunol. 2020 Jul 10;11:1648. doi: 10.3389/fimmu.2020.01648. eCollection 2020.
Zotero 插件